An evaluation of the safety of poly-ADP-ribose-polymerase inhibitors (PARPi) in ovarian cancer treatment.An analysis of the studies on PARP inhibitors, a summary of the most common and serious adverse events.According to the studies, the most common adverse events of PARPi include hematotoxicity, nausea and vomiting. Serious adverse events leading to dose reduction or treatment interruption or termination include anemia, thrombocytopenia, nausea, fatigue and hypertension.According to the results of the recent studies, the treatment of ovarian cancer with PARP inhibitors is generally safe.